In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
All content for Cures & Capital is the property of Martin Slezak and Simon Birksø and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
Leon 'Jun' Tang: Inside the Rise of China's Biotech Industry
Cures & Capital
1 hour 18 minutes
4 months ago
Leon 'Jun' Tang: Inside the Rise of China's Biotech Industry
How did China become a serious force in global biotech in just over a decade? This is the insider story of China's biotech boom! Dr. Leon 'Jun' Tang, founding partner of InScienceWeTrust BioAdvisory, joins Cures & Capital to unpack the rise of Chinese biopharma. From talent migration and government planning to innovation in ADCs and the challenges of commercialization. Chapters 00:00 - Introduction & Leon’s global background 01:13 - Guest introduction - Leon 'Jun' Tang 05:35 - Impac...
Cures & Capital
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
